Go to the list of all blogs
Arthur Evans's Avatar
published in Blogs
Sep 08, 2026
Why Is Howmet Aerospace (HWM) Stock Down -5.90% Today?

Why Is Howmet Aerospace (HWM) Stock Down -5.90% Today?

Key Takeaways

  • Howmet Aerospace (HWM) shares fell roughly 5.90% on Tuesday, sliding to about $243.98 from a prior close of $259.27.
  • The selloff extends pressure tied to Elon Musk’s announcement that SpaceX will cast industrial gas-turbine blades and vanes in-house, unsettling a key growth franchise for HWM.
  • Wall Street analysts have largely pushed back, arguing the competitive threat is overstated and that demand, not disruption, is the real signal.
  • The decline comes ahead of the company’s appearance at the Jefferies Global Industrials Conference on September 9, a potential clearing event for sentiment.
  • Traders are watching whether the stock stabilizes near technical support and whether management clarifies the SpaceX overhang this week.

Opening Summary

Howmet Aerospace Inc. (HWM), the Pittsburgh-based maker of jet-engine airfoils, industrial gas-turbine castings, fastening systems, and forged wheels, extended its recent slide on Tuesday, with shares trading down about 5.90% at $243.98 in intraday action. The decline follows a prior close of $259.27 from the previous completed session, confirming a clear move to the downside. Markets continue to digest the competitive implications of SpaceX’s plan to manufacture its own turbine blades and vanes, a development that has pressured the premium valuation attached to HWM’s fast-growing industrial gas turbine business.

SpaceX Foundry Announcement Remains the Central Catalyst

The primary driver behind the renewed selling is the lingering fallout from Elon Musk’s confirmation that SpaceX intends to cast industrial gas-turbine blades and vanes in-house at a Texas foundry. Musk described blade-and-vane casting as the single biggest bottleneck holding back new natural-gas turbines and said that bringing the work in-house could bring units online up to 18 months sooner — a shift he called a "profound game-changer."

For HWM, the concern is straightforward: the company is one of only a handful of firms worldwide capable of casting the high-temperature blades and vanes used in industrial gas turbines, a segment that has become one of its fastest-growing businesses. Investors fear that a well-funded entrant could divert future orders and erode the pricing power that scarcity has afforded the company amid surging demand from artificial-intelligence data centers.

Why Wall Street Sees the Threat as Overblown

Several major research firms have pushed back against the selloff, arguing that the market is misreading the news. Bernstein reiterated an Outperform rating, noting that SpaceX’s move is primarily aimed at securing its own power supply rather than becoming a merchant supplier of castings, and that HWM holds long-term agreements with major turbine producers that extend into 2030. Citigroup similarly maintained a Buy rating, describing the weakness as a "unique and likely short-lived opportunity" and arguing that the announcement reinforces the critical nature of Howmet's parts rather than undermining it.

The fundamental backdrop supports that view. HWM reported gas-turbine revenue growth of 39% in the first quarter, and its overall second-quarter results were strong, with revenue up 24% year over year to $2.54 billion and adjusted earnings of $1.33 per share that beat expectations. Full-year guidance was also raised. Despite this, sentiment remains fragile, and the stock has now retreated from its recent highs as investors reassess the competitive landscape.

Market Context and Trading Activity

The decline in HWM shares has been accompanied by elevated trading volume relative to the stock's recent average, reflecting active repositioning rather than a quiet drift lower. The move has unfolded alongside a broader cooling in high-multiple aerospace and industrial names that had led the market on the AI-driven power theme. While the company's core aerospace-engine and fastening businesses remain intact, the industrial gas turbine segment has been the focal point of investor anxiety because of its outsized growth contribution and rich implied valuation.

From a technical standpoint, the stock has broken below several near-term support levels and is trading well off its 52-week high, though it remains substantially higher on a year-to-date basis. The breach of recent consolidation levels has contributed to momentum-driven selling as traders exit positions ahead of the company's investor-day commentary.

What Comes Next for HWM

The immediate focus for investors is HWM’s presentation at the Jefferies Global Industrials Conference on September 9, where management may offer additional detail on capacity expansion, customer commitments, and the potential role SpaceX could play in the broader supply chain. Third-quarter earnings are expected in late October, providing a firmer read on whether the gas-turbine momentum has been disrupted. Key risks include further competitive announcements, broader market rotation away from high-valuation industrials, and any slowdown in AI-driven power demand. For now, the stock's trajectory hinges on whether management can reassure investors that its scarcity-driven pricing power remains intact.

Trending AI Robots

For traders seeking a data-driven edge in volatile markets, Tickeron's Trending AI Robots page highlights a curated selection of the platform's strongest-performing automated trading strategies. Tickeron offers hundreds of AI trading bots covering thousands of tickers, but only the most effective performers under current market conditions are featured in this section. These bots vary by strategy, timeframe, performance metrics, and traded symbols, giving investors a range of approaches to evaluate. Explore the Trending AI Robots to see which strategies are currently leading the market.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: HWM

Contributor

Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.


HWM's RSI Oscillator ascending out of oversold territory

The RSI Oscillator for HWM moved out of oversold territory on September 18, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 14 similar instances when the indicator left oversold territory. In 13 of the 14 cases the stock moved higher. This puts the odds of a move higher at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 01, 2026. You may want to consider a long position or call options on HWM as a result. In 57 of 75 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 76%.

The Moving Average Convergence Divergence (MACD) for HWM just turned positive on September 24, 2026. Looking at past instances where HWM's MACD turned positive, the stock continued to rise in 43 of 56 cases over the following month. The odds of a continued upward trend are 77%.

Following a +2.25% 3-day Advance, the price is estimated to grow further. Considering data from situations where HWM advanced for three days, in 255 of 351 cases, the price rose further within the following month. The odds of a continued upward trend are 73%.

HWM may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 41 of 72 cases where HWM's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 57%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where HWM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 50%.

The Aroon Indicator for HWM entered a downward trend on September 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Profit vs. Risk Rating rating for this company is 10 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 76, placing this stock better than average.

The Tickeron SMR rating for this company is 29 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is 54 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 58 (best 1 - 100 worst), indicating steady price growth. HWM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 71 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: HWM's P/B Ratio (15.873) is slightly higher than the industry average of (6.305). P/E Ratio (49.207) is within average values for comparable stocks, (58.116). Projected Growth (PEG Ratio) (0.450) is also within normal values, averaging (2.564). Dividend Yield (0.002) settles around the average of (0.009) among similar stocks. P/S Ratio (10.081) is also within normal values, averaging (18.330).

The Tickeron Seasonality Score of 95 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

Notable companies

The most notable companies in this group are GE Aerospace (NYSE:GE), Boeing Company (NYSE:BA), Lockheed Martin Corp (NYSE:LMT), Northrop Grumman Corp (NYSE:NOC), Virgin Galactic Holdings (NYSE:SPCE).

Industry description

Aerospace & Defense is one of largest industries in the U.S., mainly comprising the following areas: commercial airliners, military aircraft, missiles, space, and general aviation. Focused heavily on research & development, it is also one of the fastest growing industries. Military aircraft has the largest market share in the industry’s sales, followed by space systems, civil aircraft, and missiles. Aerospace exports, directly and indirectly, support more jobs than the export of any other commodity, according to a study by the U.S. Department of Commerce. Boeing Company, Lockheed Martin Corporation and General Electric Company are some of the most prominent players in this space.

Market Cap

The average market capitalization across the Aerospace & Defense Industry is 38.94B. The market cap for tickers in the group ranges from 4.49 to 1.92T. SPCX holds the highest valuation in this group at 1.92T. The lowest valued company is BDRPF at 4.49.

High and low price notable news

The average weekly price growth across all stocks in the Aerospace & Defense Industry was -1%. For the same Industry, the average monthly price growth was -8%, and the average quarterly price growth was -11%. SPCX experienced the highest price growth at 18%, while PUSA experienced the biggest fall at -21%.

Volume

The average weekly volume growth across all stocks in the Aerospace & Defense Industry was 19%. For the same stocks of the Industry, the average monthly volume growth was 41% and the average quarterly volume growth was -24%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 45
P/E Growth Rating: 70
Price Growth Rating: 62
SMR Rating: 77
Profit Risk Rating: 76
Seasonality Score: 14 (-100 ... +100)
View a ticker or compare two or three
HWM
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a company, which engages in manufacturing and engineering of lightweight metals

Industry AerospaceDefense

Industry
N/A
Address
201 Isabella Street
Phone
+1 412 553-1950
Employees
25430
Web
https://www.howmet.com
Interact to see
Advertisement
UBXG stock surged +79% over the last 30 days, driven by heightened trading volume and positive market sentiment amid broader technology sector trends. Over the past quarter, the stock rose +61%, reflecting recovery from earlier lows near its 52-week bottom.
CVGI stock surged approximately +89% over the last 30 days, driven by strong Q4 2025 earnings beat on revenue and positive 2026 guidance. Over the past quarter, shares rose about +126%, reflecting improved profitability, debt reduction, and a key partnership announcement.
SAFX stock surged +104% over the past 30 days, driven by positive updates on a $10 million capital raise and merger progress. Over the past quarter, the stock rose +44%, reflecting recovery from lows amid renewable energy sector interest and strategic developments.
LONA stock surged +80% over the past 30 days, driven by positive analyst upgrades, executive appointments, and full-year financial updates highlighting pipeline progress. Over the past quarter, shares rose +48%, reflecting improved investor sentiment in biotech amid clinical advancements.
Lifetime Brands (LCUT) stock surged +77% over the last 30 days, driven by a strong Q4 earnings beat and a Zacks Rank #1 (Strong Buy) upgrade that reflects an improved earnings outlook. Over the past quarter, shares rose +48%, supported by profitability gains despite softer sales, with adjusted EBITDA reaching $50.8 million for full-year 2025.
CURV stock surged approximately +73% over the last 30 days, driven primarily by a positive reaction to Q4 and fiscal 2025 earnings that beat expectations on EPS and revenue. Over the past quarter, the stock is up around +55%, reflecting recovery from lows near $1 amid ongoing store optimization and sub-brand launches
Blaize Holdings, Inc. (BZAI) focuses on artificial intelligence (AI)-enabled edge computing solutions, offering programmable AI processors and platforms for verticals such as smart cities, defense, retail, and enterprise markets. The company's core revolves around hardware like the Graph Streaming Processor (GSP) AI accelerator, compute cards, and software tools including Blaize AI Studio—a no-code/low-code environment for deploying AI models without source code expertise. Based in El Dorado Hills, California, and founded in 2010, it went public through a merger in early 2025.
Comstock Holding Companies, Inc. (CHCI) operates as an asset manager, developer, and operator of mixed-use and transit-oriented properties, mainly in the greater Washington, D.C. metropolitan area. The company targets high-growth urban and suburban markets, overseeing a portfolio that spans residential, commercial, hospitality, and parking assets near key metro stations. Its asset-light, fee-based model delivers recurring revenue through property management, leasing, development services, and asset recapitalization for institutional investors, family offices, and governments.
ARM stock surged +26% over the past 30 days, driven by announcements of in-house chip production and strong analyst upgrades amid AI enthusiasm. Over the past quarter, the stock climbed +38%, reflecting robust Q3 earnings beat with 26% revenue growth and data center royalty doubling.
Sable Offshore Corp. (SOC) is an independent oil and gas company focused on offshore operations in federal waters off California. The company owns and operates three platforms in the Santa Ynez Unit (SYU), spanning 16 federal leases across approximately 76,000 acres, along with subsea pipelines for crude oil, natural gas, and produced water transport to onshore facilities. Its core business model centers on restarting and developing prolific fields like the SYU, which had been idle due to regulatory and legal hurdles following a 2015 pipeline spill.
From what I see, Cheniere Energy Partners (CQP) holds a commanding position through its ownership and operation of the Sabine Pass LNG terminal in Louisiana, the largest LNG production facility in the U.S. with approximately 30 million tonnes per annum (mtpa) capacity across six trains, alongside the connected Creole Trail Pipeline. This setup makes CQP a leader in U.S. LNG exports, which have accounted for about 11% of global supply in recent years. The company's ~80% contracted production through long-term sale and purchase agreements (SPAs) provides revenue stability, with weighted average remaining lives of around 13 years.
In my view, Regeneron Pharmaceuticals holds a strong leadership position in biotechnology, thanks to its proprietary VelociSuite technologies, including VelocImmune for fully human antibody discovery. This enables a robust pipeline across immunology, oncology, ophthalmology, and rare diseases. The company's integrated model—from discovery to commercialization—drives high R&D productivity, with approximately 45 clinical programs and key partnerships like Sanofi for Dupixent and Bayer for EYLEA.
As I review argenx SE's place in the market, its strong footing in immunology stands out. This commercial-stage biopharmaceutical company focuses on differentiated antibody therapies for severe autoimmune diseases. The flagship product, VYVGART (efgartigimod), a first-in-class neonatal Fc receptor (FcRn) inhibitor, has secured leadership in generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP), with approvals across the U.S., Europe, and Japan. The Immunology Innovation Program (IIP) fuels a robust pipeline, featuring next-generation FcRn candidates like ARGX-213 and ARGX-124, alongside first-in-class assets such as empasiprubart (C2 inhibitor, ARGX-117) and adimanebart (MuSK agonist).
I've long admired Alnylam Pharmaceuticals as the pioneer in RNA interference (RNAi) therapeutics, a gene-silencing technology that has delivered six approved products, including AMVUTTRA (vutrisiran), ONPATTRO (patisiran), GIVLAARI (givosiran), and OXLUMO (lumasiran). The company's proprietary platform, enhanced by GalNAc conjugation for liver targeting and emerging extra-hepatic delivery innovations, creates a solid competitive moat in precision genetic medicines.
As I review BeOne Medicines AG's position in the oncology space, what stands out is its role as a global leader with a diversified portfolio that includes both commercial-stage therapies and a deep pipeline targeting hematologic and solid tumors. The flagship product, BRUKINSA (zanubrutinib), a Bruton's Tyrosine Kinase (BTK) inhibitor, has secured approvals in over 75 markets, solidifying its dominance in chronic lymphocytic leukemia (CLL) and other blood cancers. This is complemented by TEVIMBRA (tislelizumab), an anti-PD-1 antibody approved in more than 50 markets for various indications, which broadens its reach in immunotherapy.
Rio Tinto holds a premier position as one of the world's largest mining companies, anchored by low-cost, Tier 1 assets. Its Pilbara iron ore operations in Australia deliver industry-leading margins, thanks to integrated rail and port infrastructure that gives it a structural cost advantage over higher-cost producers. In copper, the company has significant stakes in Escondida, the world's largest copper mine, and full ownership of Oyu Tolgoi in Mongolia, setting it up well to benefit from tightening supply as demand surges for electrification and renewables.
I've always been impressed by how Visa (V) commands the global payments landscape. As an open-loop network, it connects issuers, acquirers, merchants, and consumers without issuing cards or extending credit itself. The VisaNet platform processes over 65,000 transactions per second across more than 200 countries, supporting a ~52% share of the global credit card market and ~60% of debit. This scale generates powerful network effects, where greater adoption benefits everyone involved and creates formidable barriers to entry.
Following the Kenvue consumer health spin-off, Johnson & Johnson has transformed into a focused healthcare leader, emphasizing Innovative Medicine (pharmaceuticals) and MedTech (devices). In my view, this repositioning sharpens the company's edge in high-margin areas such as oncology, immunology, neuroscience, cardiovascular, surgery, and vision, where its diversified portfolio and R&D efficiency provide clear competitive advantages.
I've long appreciated ASML Holding N.V.'s dominant position in the semiconductor lithography market. The company commands over 90% share in advanced deep ultraviolet (DUV) immersion systems and 100% in EUV lithography—the critical technology for chips below 7nm nodes used in AI, high-performance computing, and memory. This near-monopoly comes from decades of R&D investment, exclusive partnerships like Zeiss for optics, and a vast installed base that generates steady service revenue. From what I see, competitors such as Nikon and Canon remain far behind in EUV, sticking to mature nodes.
I've been watching Micron Technology (MU) closely through its recent volatility, which mirrors the semiconductor sector's heightened sensitivity to AI demand and supply constraints. The stock saw a sharp post-earnings sell-off tied to elevated capital expenditure plans, yet it has rebounded with surging DRAM prices—up 90-95%—and memory suppliers booked out for years. From what I see, broader tech optimism, including key partnerships and persistent supply tightness, is driving upward momentum. This positions MU as a pivotal player in high-bandwidth memory (HBM) for data centers. Trading near recent highs around $368, the shares highlight investor focus on Micron's critical role in the AI infrastructure expansion under these constrained industry conditions.